(5S)-5-(2-Aminoethyl)pyrrolidin-2-one | 1909286-52-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (5S)-5-(2-Aminoethyl)pyrrolidin-2-one
• CAS: 1909286-52-7
• 化学式: C₆H₁₂N₂O
• 分子量: 128.17
• InChiKey: MVONUEUNUKAERG-YFKPBYRVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME<br/>[FR] COMPOSÉS 1,1'-BIPHÉNYLE SUBSTITUÉS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ARBUTUS BIOPHARMA INC

  公开号：WO2021158481A1

  公开（公告）日：2021-08-12

  The present invention includes substituted 1,1'-biphenyl compounds, analogues thereof, and compositions comprising the same. In one aspect, the compounds contemplated in the invention can be used to treat, ameliorate, or prevent hepatitis B virus (HBV) and/or hepatitis D virus (HDV) infections in a patient. In another aspect, the compounds contemplated in the invention can be used to treat, ameliorate, and/or prevent cancer in a patient.

  本发明包括取代的1,1'-联苯化合物，其类似物，以及包含它们的组合物。在一个方面，本发明中考虑的化合物可用于治疗、改善或预防患者体内的乙型肝炎病毒（HBV）和/或丙型肝炎病毒（HDV）感染。在另一个方面，本发明中考虑的化合物可用于治疗、改善和/或预防患者体内的癌症。
• [EN] BETA-LACTAMASE INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE BÊTA-LACTAMASE
  申请人：ENTASIS THERAPEUTICS LTD

  公开号：WO2018053215A1

  公开（公告）日：2018-03-22

  The present invention is directed to compounds which are beta-lactamase inhibitors. The compounds and their pharmaceutically acceptable salts are useful in combination with beta- lactam antibiotics, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3, R4, R5 and R6 are described herein.

  本发明涉及β-内酰胺酶抑制剂化合物。这些化合物及其药用盐与β-内酰胺类抗生素结合使用，用于治疗细菌感染，包括由耐药性生物引起的感染，包括多药耐药生物引起的感染。本发明包括根据式（I）描述的化合物：或其药用可接受盐，其中R1、R2、R3、R4、R5和R6的值在此处描述。
• [EN] TRIARYL COMPOUNDS FOR TREATMENT OF PD-L1 DISEASES<br/>[FR] COMPOSÉS TRIARYLES POUR LE TRAITEMENT DE MALADIES PD-L1
  申请人：CHEMOCENTRYX INC

  公开号：WO2020232256A1

  公开（公告）日：2020-11-19

  Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  提供了一些作为免疫调节剂有用的化合物。这些化合物具有公式（I），包括立体异构体和其药用盐，其中R1a、R1b、R1c、R1d、R2a、R2b、R3、R3a、R4、R6、R7、R8、A、Z、X1和n如本文所定义。还披露了与这些化合物的制备和使用相关的方法，以及包含这些化合物的药物组合物。
• Beta-lactamase inhibitor compounds
  申请人：Entasis Therapeutics Limited

  公开号：US10800778B2

  公开（公告）日：2020-10-13

  The present invention is directed to compounds which are beta-lactamase inhibitors. The compounds and their pharmaceutically acceptable salts are useful in combination with beta-lactam antibiotics, for the treatment of bacterial infections, including infections caused by drug resistant organisms, including multi-drug resistant organisms. The present invention includes compounds according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of R1, R2, R3, R4, R5 and R6 are described herein.

  本发明涉及作为β-内酰胺酶抑制剂的化合物。这些化合物及其药学上可接受的盐与β-内酰胺类抗生素联合使用，可用于治疗细菌感染，包括由耐药生物体（包括多重耐药生物体）引起的感染。本发明包括符合式（I）的化合物：或其药学上可接受的盐，其中 R1、R2、R3、R4、R5 和 R6 的值如本文所述。
• BETA-LACTAMASE INHIBITOR COMPOUNDS
  申请人：Entasis Therapeutics Limited

  公开号：EP3512851A1

  公开（公告）日：2019-07-24